Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 7/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18757223 | 0.90 | GBA1 (0.44) | GBA1HRH4HRH3FOLH1EPHX2 | |
| SCHEMBL22246883 | 0.90 | GBA1 (0.44) | GBA1HRH4HRH3EPHX2CYP19A1 | |
| SCHEMBL18757224 | 0.90 | GBA1 (0.47) | GBA1HRH4HRH3EPHX2ADRB2 | |
| SCHEMBL3435452 | 0.90 | HRH4 (0.47) | GBA1HRH4HRH3FOLH1EPHX2 | |
| SCHEMBL20364737 | 0.89 | HRH4 (0.48) | GBA1HRH4HRH3FOLH1EPHX2 | |
| SCHEMBL14648773 | 0.89 | HRH4 (0.48) | GBA1HRH4HRH3FOLH1EPHX2 | |
| SCHEMBL20099165 | 0.87 | GBA1 (0.46) | GBA1HRH4HRH3FOLH1EPHX2 | |
| SCHEMBL20364736 | 0.87 | HRH4 (0.47) | GBA1HRH4HRH3FOLH1EPHX2 | |
| SCHEMBL18160354 | 0.86 | HRH4 (0.48) | GBA1HRH4HRH3FOLH1EPHX2 | |
| SCHEMBL3434906 | 0.86 | HRH4 (0.48) | GBA1HRH4HRH3FOLH1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308699-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170226177-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308699-B2 | Peptidomimetic macrocycles | GHRHR, GHSR, GHITM | GBA1 1351/4885HRH4 1954/4885HRH3 2166/4885 |
| US-20170226177-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | GBA1 1351/4885HRH4 1954/4885HRH3 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.